United Therapeutics Announces FDA Approval of Tyvaso DPI - Seite 2
FDA approval of the new drug application for Tyvaso DPI is supported by data from BREEZE, an open label study of 51 PAH patients on a stable regimen of Tyvaso Inhalation Solution who were transitioned to Tyvaso DPI. In subjects with PAH, transition from Tyvaso Inhalation Solution to Tyvaso DPI demonstrated safety and tolerance during the three-week treatment phase with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes. Top line data from BREEZE were issued in January 2021, efficacy data were presented in September 2021, long-term open-label safety data were published in April 2022, and additional long-term safety and efficacy data were presented in May 2022. See the Important Safety Information below under “About Tyvaso DPI”.
About PAH
Also known as World Health Organization (WHO) Group 1 Pulmonary Hypertension, PAH is life-threatening high blood pressure in the arteries of the lungs, affecting the
ability of the heart and lungs to work properly in afflicted patients. PAH is a serious, progressive disease for which there is no known cure. PAH affects an estimated 45,000 patients in the United
States.
About PH-ILD
Interstitial lung disease is a group of lung diseases that are characterized by marked scarring or fibrosis of the bronchioles and alveolar sacs within the lungs.
Increased fibrotic tissue in ILD prevents oxygenation and free gas exchange between the pulmonary capillaries and alveolar sacs, and the condition can present with a wide range of symptoms,
including shortness of breath with activity, labored breathing, and fatigue. Pulmonary hypertension frequently complicates the course of patients with ILD and is associated with worse functional
status measured by exercise capacity, greater supplemental oxygen needs, decreased quality of life, and worse outcomes.
PH-ILD is estimated to affect at least 15% of patients with ILD (approximately 30,000 PH-ILD patients) and may affect up to 86% of patients with more severe ILD. PH-ILD is included within Group 3 of the WHO classification of PH.
About TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder
Eyebrow (abbreviated) Indication
- For the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
- For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
INDICATION